The change in leadership does not alter SciBase strategy or overarching goals. All plans remain firmly in place, with a focus on the U.S. market and securing reimbursement for the use of Nevisense in skin cancer diagnostics. A top priority is also the collaboration with Castle Biosciences, which will lead to an expanded offering and increased use of Nevisense. SciBase has an experienced, strong, and well-composed management team that collectively drives the company's growth agenda, providing a stable foundation as the Board recruits a new CEO. The U.S. organization, led by Leda Beaty, is well-equipped to continue driving development in the American market.
"Pia Renaudin has played a crucial role during her years as CEO in shaping the strategy, structure, and organization to ensure SciBase can fully capitalize on the potential of Nevisense," says Jesper Hoiland, Chairman of the Board of SciBase. "Under her leadership, the company has strengthened its position in the U.S. market and built an organization with the right expertise to broaden the use of Nevisense and drive development forward in the U.S. On behalf of the Board and myself, I would like to extend our deepest gratitude to Pia for her contributions and driven leadership. We wish her the best in her new role."
"SciBase is now entering a new phase where the strategy and foundation is in place, and I feel this is the right time to hand over responsibility to a new CEO. I am incredibly proud of the fantastic development the company has achieved in recent years. The U.S. organization is doing an outstanding job, and an experienced management team is in place to guide the company through the next phase. Against this backdrop, it feels like the right moment for me to move on and take on a new challenge. I would like to extend my warmest thanks to Jesper and the Board, the management team, and all employees for their incredible efforts in striving to improve cancer diagnostics and save patients' lives," says Pia Renaudin.
The Board has now initiated a recruitment process to find Pia Renaudin's successor.
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 09.00 CET on July 28 2026.
About SciBase and Nevisense SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
Nevisense is currently the only FDA-approved AI-driven technology in dermatology for the assessment and early detection of melanoma. If cleared, the expanded indication would extend the clinical utility of the existing Nevisense platform to include non-melanoma skin cancers, representing a significant expansion of its addressable U.S. market.
Non-Melanoma Skin Cancer Burden
More than 5.41,2) million cases of basal cell carcinoma and squamous cell carcinoma are diagnosed annually in the United States, making keratinocyte skin cancer the most common form of cancer. Delayed diagnosis can lead to, in the case of squamous cell carcinoma, metastatic disease, highlighting the need for objective technologies that support earlier clinical assessment and more informed biopsy decisions.
The submitted 510(k) premarket notification seeks to expand Nevisense's indication to include lesions with characteristics of keratinocyte skin cancer. In Europe, Nevisense is already CE marked for use in both melanoma and keratinocyte skin cancer, making the U.S. submission an important milestone in SciBase's strategy to broaden the clinical application of its technology.
"This submission represents an important milestone for SciBase and our strategy to expand the clinical applications of Nevisense in the United States," said Pia Renaudin, Chief Executive Officer of SciBase. "Keratinocyte skin cancer is estimated to be the most common form of cancer, and we believe Nevisense has the potential to provide dermatologists with objective decision support across an even broader range of suspicious skin lesions. Expanding Nevisense beyond melanoma represents an important step toward supporting clinicians across the broader spectrum of skin cancers encountered in daily dermatology practice. We look forward to working closely with the FDA throughout the review process."
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.30 CET on July 1, 2026.
About SciBase and Nevisense SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
American Cancer Society. Cancer Facts & Figures 2025. (Melanoma incidence and ranking in the United States.)
American Academy of Dermatology. Approximately 5.4 million cases of basal cell carcinoma and squamous cell carcinoma are diagnosed annually in the United States.
The primary objective of the multicenter prospective clinical study is to assess the prediction of flares in atopic dermatitis (AD). This milestone marks a significant step forward in understanding and managing this chronic, inflammatory skin condition, which affects millions of people worldwide.
The study, titled DETECT-AD, the first study through the collaboration with Castle Biosciences, will investigate SciBase method of Electrical Impedance Spectroscopy (EIS) ability to predict the onset of flares in patients with atopic dermatitis. By identifying early signs, the research aims to enable proactive interventions, improve patient quality of life, and reduce the burden of unpredictable flare-ups.
Atopic dermatitis is characterized by periods of remission and flare-ups, which can significantly impact patients' daily lives. Current treatment approaches are often reactive, addressing symptoms only after they appear. This study seeks to shift the paradigm toward proactive, personalized care, empowering patients and healthcare providers with actionable insights.
"The enrollment of the first patient is an exciting milestone in our mission to transform the management of atopic dermatitis. By predicting flares before they occur, we hope to offer patients greater control over their condition and improve their overall well-being", said Pia Renaudin, CEO of SciBase.,
About SciBase and Nevisense SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
The study, which was previously orally presented at the AAAAI conference in Philadelphia February 27 - March 2, was conducted by researchers at the Icahn School of Medicine at Mount Sinai and assessed neonatal skin barrier integrity using Nevisense within the first days of life. Infants who developed atopic dermatitis during their first year had significantly higher neonatal measurements than those who remained disease-free, suggesting that Nevisense may serve as a non-invasive early biomarker of skin barrier dysfunction associated with future atopic dermatitis risk.
Atopic dermatitis affects approximately 15-20% of children worldwide and is one of the most common chronic inflammatory skin diseases of infancy and childhood.1) It is often the first manifestation of the "atopic march," a progression that may later include food allergies, asthma, and allergic rhinitis. The ability to identify skin barrier dysfunction before the onset of clinical symptoms could enable earlier risk assessment, support future prevention strategies, and improve patient stratification in both clinical practice and research
Conclusion from the study was "Higher EIS scores, suggestive of impaired skin barrier, within the first week of life were significantly associated with development of AD in the first year of life."
"The publication of these findings in a leading peer-reviewed allergy journal represents an important milestone", said Pia Renaudin, CEO of SciBase. "These results support the potential of Nevisense not only as a technology for assessing skin barrier integrity, but also as an early biomarker that may help identify infants at increased risk of developing atopic dermatitis before clinical symptoms emerge."
The publication adds to a growing body of evidence supporting Nevisense as a non-invasive technology platform for assessing skin barrier integrity and dysfunction. Together with previous studies, these findings further strengthen the potential role of Nevisense in earlier risk assessment, prevention strategies, disease monitoring, and future therapeutic development in atopic dermatitis and other skin barrier disorders.
The authors conclude that reliable, non-invasive technologies for assessing skin barrier integrity remain an important unmet need. Their findings demonstrate the potential of Nevisense to detect early skin barrier dysfunction and identify infants at elevated risk for atopic dermatitis before disease onset.
The article titled" Elevated Neonatal Electrical Impedance Spectroscopy Measurements Are Associated With Atopic Dermatitis in High-Risk Infants" is published in the journal Allergy and can be found through this link: https://onlinelibrary.wiley.com/doi/10.1111/all.70402,
About SciBase and Nevisense SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
The board of directors' resolution entails that the last day of trading in the Company's share, before the Reverse Share Split, will be on 3 June 2026, and the first day of trading in the Company's share, after the Reverse Share Split, will be on 4 June 2026. This means that the share price as of 4 June 2026 will reflect the effect of the Reverse Share Split. As a result of the Reverse Share Split, the Company's share will have a new ISIN code as of 4 June 2026: SE0029277631.
Shareholders will automatically receive a new, lower number of shares in proportion to the number of shares held on the record date. If a shareholder's shareholding on the record date does not correspond to a full number of new shares, i.e., is not evenly divisible by one hundred (100), such shareholder will receive as many shares as necessary free of charge (1-99) that their shareholding, after adding the shares provided, becomes evenly divisible by one hundred (100), so-called rounding up. Provision of shares is made through Euroclear Sweden AB, without the need for further measures to be taken by shareholders.
Following the Reverse Share Split, the number of shares and votes in the Company will decrease from 1,022,530,000 to 10,225,300, each share with a quota value of SEK 5.00.
Timetable for the Reverse Share Split
The following timetable applies to the Reverse Share Split:
Date
Action
3 June 2026
Last day of trading in the Company's share before the Reverse Share Split.
4 June 2026
First day of trading in the Company's share following the Reverse Share Split. As of this date, the share price reflects the effect of the Reverse Share Split.
5 June 2026
Record date for the Reverse Share Split.
8 June 2026
The new number of shares is expected to be registered in each shareholder's VPC account.
Recalculation of warrants of series TO 2
In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April 2024, the number of shares that each warrant entitles the holder to subscribe for and the subscription price shall be recalculated following reverse share splits. Accordingly, the Company has carried out a recalculation of warrants of series T0 2 due to the Reverse Share Split. Following the completed recalculation, SciBase can announce that the number of shares that each warrant of series TO 2 entitles to subscribe for and the subscription price per share has changed in accordance with the following. Following the recalculation, one (1) warrant of series TO 2 entitles the holder to subscribe for 0.0109 shares at a subscription price of SEK 38.00 per share, in accordance with the previously communicated terms and conditions for the warrants.
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
In the study, human ex vivo skin samples were exposed to Sodium dodecyl sulfate (SDS), a surfactant in household cleaning products which is known to impair the barrier.
Also, skin that was affected by SDS were treated with N-acetylcysteine (NAC) and nicotinamide (NAM) to promote recovery of skin barrier function.
Nevisense was used in the study to detect the changes in the skin barrier and detected that short-term exposure to SDS rapidly disrupts human skin barrier integrity within minutes as well as the effect of NAC and NAM.
Skin barrier research is an expanding area in dermatology. Disruption of skin barrier function plays a key role in the development and severity of e.g. contact dermatitis from chemical substances
"We are happy to see that Nevisense and EIS-technology continue to provide value in this type of research. This study further strengthens the role of Nevisense as an effective research device and show the potential to become the state-of-the-art research tool within the skin barrier research," said Pia Renaudin, CEO of SciBase.
The full results of the study have now been published in the scientific journal Allergy "Rapid Human Skin Barrier Disruption by Sodium Dodecyl Sulfate and Associated Molecular Mechanisms," - Li - Allergy, DOI: https://doi.org/10.1111/all.70390
Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2025;
that no dividend shall be paid for the financial year 2025 and that the year's result shall be carried forward;
to grant the board members and the CEO discharge from liability for the financial year 2025;
that the board of directors shall consist of four ordinary members without deputy members and that a registered accounting firm shall be elected as auditor;
that the fees payable to the board of directors for the period until the end of the next annual general meeting shall be SEK 415,000 for the chairman of the board and SEK 150,000 to each of the other ordinary board members (who are not employed by a larger shareholder in the Company) and that fees payable to the auditor are to be paid in accordance with approved invoices;
for the period until the end of the next annual general meeting, to re-elect Jesper Høiland, Robert Molander, Diana Ferro and Anna Eriksrud as board members, to re-elect Jesper Høiland as chairman of the board of directors and to elect the auditing firm Öhrlings PricewaterhouseCoopers AB as auditor for the Company, with Magnus Lagerberg as auditor in charge;
to adopt principles for the appointment of a nomination committee;
to amend the articles of association and to carry out a reverse share split, whereby one hundred (100) existing shares will be consolidated into one (1) new share (reverse share split 1:100). Following registration of the reverse share split with the Swedish Companies Registration Office, the quota value per share increases from SEK 0.05 to SEK 5.00;
to implement stock option program consisting of a directed issue of warrants and approval of transfer of warrants for the fulfillment of the Company's obligations under the stock option program; and
to authorize the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures. Through issuances resolved upon with support from the authorisation - with deviation from the shareholders' preferential rights - the number of shares issued, or number of shares created in connection with exercise of warrants or conversion of convertibles, shall correspond to not more than a 20 per cent dilution of the share capital and the number of shares and votes in the Company after such issue(s).
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
While Nevisense is already an established technology for the detection of melanoma and the assessment of skin barrier in conditions like atopic dermatitis, this new research expands its potential application into the field of geriatric dermatology and longevity science.
Key Findings from the Study: The cross-sectional study compared EIS measurements between young adults (mean age 25.9) and older adults (mean age 79.1). By utilizing advanced feature-level analysis of the 700 parameters captured by each Nevisense measurement, researchers developed a "composite barrier score." Key highlights include:
Precision Detection: The study identified 35 specific age-associated EIS features in the forearm.
Strong Correlation: The resulting composite barrier score showed a strong association with age (Spearman rho=0.69), proving that EIS can detect subtle alterations in skin architecture and composition that occur as we age.
Advanced Analytics: The research emphasizes that analyzing specific EIS features provides a significantly more sensitive assessment of age-related barrier changes than standard summarized values.
"These results are an exciting step forward for SciBase," said Pia Renaudin, CEO of SciBase. "Understanding how the skin barrier evolves with age is critical for both clinical dermatology and the development of targeted skincare. This study reinforces that our EIS technology is not just a diagnostic tool for skin cancer, but a versatile platform for deep, non-invasive skin analysis." The abstract, titled " Electrical impedance spectroscopy detects age-related skin barrier changes " (See abstract No 591 in abstract booklet SID_Chcago26_Abstract_Final_web.pdf ) concludes that EIS shows significant potential for detecting age-related barrier changes in vivo. SciBase looks forward to further validation of these findings in additional cohorts to refine the composite barrier score for clinical and research use.
About SciBase and Nevisense SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
Net sales were TSEK 14,278 (8,856), +61%, cleared for currency effects +80%.
The loss after tax was TSEK 24,490 (20,682).
The loss per share was SEK 0.03 (0.07).
The cash flow from current operations was negative in the amount of TSEK 26,573 (26,001).
The gross margin was 49.2% (70.5%).
Electrode sales volume increased by 70% and was 30,460 (17,870) units. Repeat sales of electrodes to existing customers increased by 73% (incl deliveries to Castle).
Important events during the quarter
Overall sales increased by 61% (+80%, before currency effects). Sales in Germany within the skin cancer segment were at the same level as Q1-25(increased by 5% in local currency). Sales in the US skin cancer market increased by 79% (109% in local currency) while the sales within the skin barrier segment increased by 1,042%.
The gross margin was negatively affected in the quarter by the currency development (negative impact of over 5%), continued deliveries of products to Castle Biosciences for clinical studies, increased price on gold and continued investments to ramp up production.
SciBase announced the outcome of the offer to repurchase outstanding warrants of series TO 2. In total, 83.9% of the TO2 holders accepted the offer.
SciBase announced the outcome of the performed rights issue, where the issue was subscribed to 96.4% and provides the company with approximately SEK 80 million before issue costs.
A new study demonstrates that Nevisense can predict atopic dermatitis in Newborns.
Dr Hess, a US physician at Center City Dermatology in Philadelphia, published a clinical article describing his real-world experience with Nevisense in improving melanoma detection.
A recalculation of the terms for the remaining TO 2 warrants has been carried out after the completion of the rights issue.
Nevisense (EIS) included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma.
SciBase receives approval from the FDA for extended labelling in the US.
Important events after the end of the period
SciBase reaches milestone with over 400,000 tests sold globally.
SciBase published the notice to attend the 2026 AGM.
SciBase published the annual report for 2025.
Financial overview
Apr 1, 2025 -
Jan 1 - Mar 31
Mar 31, 2026
Jan 1 - Dec 31
THE GROUP
2026
2025
Rolling-12
2025
Net sales, SEK ths
14 278
8 856
45 883
40 461
Gross margin, %
49,2%
70,5%
60,8%
67,0%
Equity/Asset ratio, %
56,0%
71,6%
61,8%
12,8%
Net indebtness, multiple
0,78
0,40
0,62
6,84
Cash equivalents, SEK ths
71 255
34 295
71 255
22 604
Cashflow from operating activities, SEK ths
-26 573
-26 001
-85 150
-84 579
Earnings per share (before and after dilution), SEK
-0,03
-0,07
-0,19
-0,24
Shareholder's equity per share, SEK
0,07
0,14
0,10
0,02
Average number of shares, 000'
819 748
298 710
490 616
360 357
Number of shares at closing of period, 000'
1 022 530
338 296
1 022 530
414 183
Share price at end of period, SEK
0,35
0,42
0,35
0,29
Number of sold electrodes, pieces
30 460
17 870
98 770
86 180
Average number of employees
46
35
33
37
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on May 7, 2026.
This interim report report has not been subject to review by the Company’s auditors
About SciBase and Nevisense SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
